Search tips
Search criteria 


Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Ann Rheum Dis. 1998 September; 57(9): 545–549.
PMCID: PMC1752740

Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout


OBJECTIVES—To study the efficacy of allopurinol and benzbromarone to reduce serum urate concentrations in patients with primary chronic gout.
METHODS—Prospective, parallel, open study of 86 consecutive male patients with primary chronic gout. Forty nine patients (26 normal excretors and 23 under excretors) were given allopurinol 300 mg/day and 37 under excretors benzbromarone 100 mg/day. After achieving steady plasma urate concentrations with such doses, treatment was then adjusted to obtain optimal plasmatic urate concentrations (under 6 mg/dl).
RESULTS—Patients receiving allopurinol 300 mg/day showed a mean reduction of plasmatic urate of 2.75 mg/dl (from 8.60 to 5.85 mg/dl) and 3.34 mg/dl (from 9.10 to 5.76 mg/dl) in normal excretors and under excretors respectively. Patients receiving benzbromarone 100 mg/day achieved a reduction of plasmatic urate of 5.04 mg/dl (from 8.58 to 3.54 mg/dl). Fifty three per cent of patients receiving allopurinol and 100% receiving benzbromarone achieved optimal plasma urate concentrations at such doses. The patients with poor results with allopurinol 300 mg/day achieved a proper plasma urate concentration with allopurinol 450 to 600 mg/day, the mean final dose being 372 mg/day. Renal fuction improved and no case of renal lithiasis was observed among benzbromarone treated patients, whose mean final dose was 76 mg/day.
CONCLUSION—Benzbromarone is very effective to control plasma urate concentrations at doses ranging from 50 to 100 mg/day. Uricosuric treatment is a suitable approach to the treatment of patients with gout who show underexcretion of urate.

Keywords: gout; gout suppressants; allopurinol; benzbromarone

Full Text

The Full Text of this article is available as a PDF (121K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Yü T, Yu TF. Milestones in the treatment of gout. Am J Med. 1974 May;56(5):676–685. [PubMed]
  • Palella TD, Kelley WN. An approach to hyperuricemia and gout. Geriatrics. 1984 Nov;39(11):89–102. [PubMed]
  • Wallace SL, Singer JZ. Therapy in gout. Rheum Dis Clin North Am. 1988 Aug;14(2):441–457. [PubMed]
  • Diamond HS. Control of crystal-induced arthropathies. Rheum Dis Clin North Am. 1989 Aug;15(3):557–567. [PubMed]
  • Fam AG. Strategies and controversies in the treatment of gout and hyperuricaemia. Baillieres Clin Rheumatol. 1990 Aug;4(2):177–192. [PubMed]
  • Fam AG. Should patients with interval gout be treated with urate lowering drugs? J Rheumatol. 1995 Sep;22(9):1621–1623. [PubMed]
  • Simkin PA. Management of gout. Ann Intern Med. 1979 May;90(5):812–816. [PubMed]
  • Ferraz MB. An evidence based appraisal of the management of nontophaceous interval gout. J Rheumatol. 1995 Sep;22(9):1618–1619. [PubMed]
  • Ferraz MB, O'Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol. 1995 May;22(5):908–914. [PubMed]
  • Rosenthal AK, Ryan LM. Treatment of refractory crystal-associated arthritis. Rheum Dis Clin North Am. 1995 Feb;21(1):151–161. [PubMed]
  • Fiddis RW, Vlachos N, Calvert PD. Studies of urate crystallisation in relation to gout. Ann Rheum Dis. 1983 Aug;42 (Suppl 1):12–15. [PMC free article] [PubMed]
  • Gast LF. Reduce serum uric acid levels before withdrawing antihyperuricemic therapy in patients with tophaceous gout. Arthritis Rheum. 1992 Oct;35(10):1252–1252. [PubMed]
  • Emmerson BT. The management of gout. N Engl J Med. 1996 Feb 15;334(7):445–451. [PubMed]
  • Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977 Apr;20(3):895–900. [PubMed]
  • Ralston SH, Capell HA, Sturrock RD. Alcohol and response to treatment of gout. Br Med J (Clin Res Ed) 1988 Jun 11;296(6637):1641–1642. [PMC free article] [PubMed]
  • Nicholls A, Scott JT. Effect of weight-loss on plasma and urinary levels of uric acid. Lancet. 1972 Dec 9;2(7789):1223–1224. [PubMed]
  • Puig JG, Mateos FA, Jiménez ML, Ramos TH. Renal excretion of hypoxanthine and xanthine in primary gout. Am J Med. 1988 Oct;85(4):533–537. [PubMed]
  • Kaehny WD, Tangel DJ, Johnson AM, Kimberling WJ, Schrier RW, Gabow PA. Uric acid handling in autosomal dominant polycystic kidney disease with normal filtration rates. Am J Med. 1990 Jul;89(1):49–52. [PubMed]
  • McCarthy GM, Barthelemy CR, Veum JA, Wortmann RL. Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout. Arthritis Rheum. 1991 Dec;34(12):1489–1494. [PubMed]
  • Bull PW, Scott JT. Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol. 1989 Sep;16(9):1246–1248. [PubMed]
  • Loebl WY, Scott JT. Withdrawal of allopurinol in patients with gout. Ann Rheum Dis. 1974 Jul;33(4):304–307. [PMC free article] [PubMed]
  • Nakayama DA, Barthelemy C, Carrera G, Lightfoot RW, Jr, Wortmann RL. Tophaceous gout: a clinical and radiographic assessment. Arthritis Rheum. 1984 Apr;27(4):468–471. [PubMed]
  • van Lieshout-Zuidema MF, Breedveld FC. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. J Rheumatol. 1993 Aug;20(8):1383–1385. [PubMed]
  • Gast LF. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. Clin Rheumatol. 1987 Mar;6(1):70–73. [PubMed]
  • Boss GR, Seegmiller JE. Hyperuricemia and gout. Classification, complications and management. N Engl J Med. 1979 Jun 28;300(26):1459–1468. [PubMed]
  • Wolfe F, Cathey MA. The misdiagnosis of gout and hyperuricemia. J Rheumatol. 1991 Aug;18(8):1232–1234. [PubMed]
  • Bellamy N, Gilbert JR, Brooks PM, Emmerson BT, Campbell J. A survey of current prescribing practices of antiinflammatory and urate lowering drugs in gouty arthritis in the province of Ontario. J Rheumatol. 1988 Dec;15(12):1841–1847. [PubMed]
  • Harris CM, Lloyd DC, Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol. 1995 Sep;48(9):1153–1158. [PubMed]
  • Cutrín Prieto C, Nieto Pol E, Batalla Eiras A, Casal Iglesias L, Pérez Becerra E, Lorenzo Zúiga V. Hepatitis tóxica por cincofeno: descripción de tres enfermos. Med Clin (Barc) 1991 Jun 15;97(3):104–106. [PubMed]
  • Sinclair DS, Fox IH. The pharmacology of hypouricemic effect of benzbromarone. J Rheumatol. 1975 Dec;2(4):437–445. [PubMed]
  • Sorensen LB, Levinson DJ. Clinical evaluation of benzbromarone: a new uricosuric drug. Arthritis Rheum. 1976 Mar-Apr;19(2):183–190. [PubMed]
  • Masbernard A, Giudicelli CP. Ten years' experience with benzbromarone in the management of gout and hyperuricaemia. S Afr Med J. 1981 May 9;59(20):701–706. [PubMed]
  • Zürcher RM, Bock HA, Thiel G. Excellent uricosuric efficacy of benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study. Nephrol Dial Transplant. 1994;9(5):548–551. [PubMed]
  • Asplin JR. Uric acid stones. Semin Nephrol. 1996 Sep;16(5):412–424. [PubMed]
  • Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum. 1986 Jan;29(1):82–87. [PubMed]
  • Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984 Jan;76(1):47–56. [PubMed]
  • Cummins D, Sekar M, Halil O, Banner N. Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Transplantation. 1996 Jun 15;61(11):1661–1662. [PubMed]
  • Walter-Sack I, de Vries JX, von Bubnoff A, Pfleilschifter V, Raedsch R. Biotransformation and uric acid lowering effect of benzbromarone in patients with liver cirrhosis - evidence for active benzbromarone metabolites? Eur J Med Res. 1995 Oct 16;1(1):16–20. [PubMed]
  • van der Klauw MM, Houtman PM, Stricker BH, Spoelstra P. Hepatic injury caused by benzbromarone. J Hepatol. 1994 Mar;20(3):376–379. [PubMed]
  • Gehenot M, Horsmans Y, Rahier J, Geubel AP. Subfulminant hepatitis requiring liver transplantation after benzarone administration. J Hepatol. 1994 Jun;20(6):842–842. [PubMed]
  • Hautekeete ML, Henrion J, Naegels S, DeNeve A, Adler M, Deprez C, Devis G, Klöppel G. Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities. Liver. 1995 Feb;15(1):25–29. [PubMed]

Figures and Tables

Figure 1
Initial and final plasma urate (Pur) (fig 1A) and 24 hour urinary urate (24 h Uur) (fig 1B) after standard doses of urate lowering drugs (allopurinol 300 mg/day or benzbromarone 100 mg/day). Note that the mean initial ...

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group